Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Income towards Parent Company: 2013-2024

Historic Income towards Parent Company for Aclaris Therapeutics (ACRS) over the last 12 years, with Dec 2024 value amounting to -$132.1 million.

  • Aclaris Therapeutics' Income towards Parent Company fell 80.78% to -$15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$145.2 million, marking a year-over-year decrease of 279.49%. This contributed to the annual value of -$132.1 million for FY2024, which is 49.26% down from last year.
  • According to the latest figures from FY2024, Aclaris Therapeutics' Income towards Parent Company is -$132.1 million, which was down 49.26% from -$88.5 million recorded in FY2023.
  • Aclaris Therapeutics' 5-year Income towards Parent Company high stood at $139,000 for FY2020, and its period low was -$132.1 million during FY2024.
  • Over the past 3 years, Aclaris Therapeutics' median Income towards Parent Company value was -$88.5 million (recorded in 2023), while the average stood at -$102.5 million.
  • In the last 5 years, Aclaris Therapeutics' Income towards Parent Company soared by 100.29% in 2020 and then plummeted by 65,470.50% in 2021.
  • Yearly analysis of 5 years shows Aclaris Therapeutics' Income towards Parent Company stood at $139,000 in 2020, then plummeted by 65,470.50% to -$90.9 million in 2021, then climbed by 4.35% to -$86.9 million in 2022, then fell by 1.81% to -$88.5 million in 2023, then plummeted by 49.26% to -$132.1 million in 2024.